Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 6/20 | 0.65 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.64 |
| ▸ | MEN1 | O00255 | 1/20 | 0.64 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.64 |
| ▸ | HTT | P42858 | 1/20 | 0.64 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.64 |
| ▸ | MAPT | P10636 | 2/20 | 0.59 |
| ▸ | RAB9A | P51151 | 1/20 | 0.54 |
| ▸ | HRH2 | P25021 | 3/20 | 0.53 |
| ▸ | HRH1 | P35367 | 3/20 | 0.53 |
| ▸ | DRD2 | P14416 | 1/20 | 0.50 |
| ▸ | MAOB | P27338 | 1/20 | 0.50 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3824026 | 0.92 | KDM4E (0.64) | HRH3KDM4EMEN1ALDH1A1HTT | |
| SCHEMBL4101085 | 0.86 | KDM4E (0.66) | HRH3KDM4EMEN1ALDH1A1HTT | |
| SCHEMBL4101087 | 0.86 | KDM4E (0.66) | HRH3KDM4EMEN1ALDH1A1HTT | |
| SCHEMBL4101089 | 0.86 | KDM4E (0.66) | HRH3KDM4EMEN1ALDH1A1HTT | |
| SCHEMBL2025211 | 0.86 | HRH3 (0.64) | HRH3KDM4EMEN1ALDH1A1HTT | |
| SCHEMBL1979241 | 0.85 | HRH3 (0.70) | HRH3KDM4EMEN1ALDH1A1HTT | |
| Hydrochloric Acid SCHEMBL1977487 | 0.85 | HRH3 (0.62) | HRH3KDM4EMEN1ALDH1A1HTT | |
| SCHEMBL1977578 | 0.84 | HRH3 (0.90) | HRH3HRH2HRH1MAOB | |
| SCHEMBL1978514 | 0.83 | HRH3 (0.64) | HRH3HRH2HRH1MAOB | |
| Hydrochloric Acid SCHEMBL1979057 | 0.83 | HRH3 (0.88) | HRH3HRH2HRH1MAOB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8008337-B2 | Azabicyclo[3.2.0] hept-3-yl compounds, a process for their preparation and pharmaceutical compositions containing them | LES LABORATOIRES SERVIER (FR) | 2011-08-30 | — | — | US | disclosed |
| US-20110136886-A1 | Azabicyclo[3.2.0] hept-3-yl compounds, a process for their preparation and pharmaceutical compositions containing them | LES LABORATOIRES SERVIER (FR) | 2011-06-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110136886-A1 | Azabicyclo[3.2.0] hept-3-yl compounds, a process for their preparation and pharmaceutical compositions containing them | HRH2, HRH4, HRH3 | HRH3 3/4885KDM4E 421/4885MEN1 2158/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.